Loading...
Nanollose Limited
NC6.AX•ASX
Healthcare
Biotechnology
A$0.08
A$0.004(5.06%)
Nanollose Limited (NC6.AX) Financial Performance & Income Statement Overview
Review Nanollose Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-96.97%
↓ 96.97%
Operating Income Growth
1.78%
↑ 1.78%
Net Income Growth
14.05%
↑ 14.05%
Operating Cash Flow Growth
10.92%
↑ 10.92%
Operating Margin
-7974.08%
↓ 7974.08%
Gross Margin
-1477.91%
↓ 1477.91%
Net Profit Margin
-8208.56%
↓ 8208.56%
ROE
342.35%
↑ 342.35%
ROIC
231.10%
↑ 231.10%
Nanollose Limited (NC6.AX) Income Statement & Financial Overview
Review Nanollose Limited's (NC6.AX) income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $5007.00 | $11626.00 | $292413.00 | $412164.00 |
| Cost of Revenue | $129552.00 | $132902.00 | $228551.00 | $163362.00 |
| Gross Profit | -$124545.00 | -$121276.00 | $63862.00 | $248802.00 |
| Gross Profit Ratio | -$24.87 | -$10.43 | $0.22 | $0.60 |
| R&D Expenses | $129552.00 | $132902.00 | $228551.00 | $163362.00 |
| SG&A Expenses | $440321.00 | $377733.00 | $453225.00 | $474615.00 |
| Operating Expenses | $569873.00 | $510635.00 | $681776.00 | $637977.00 |
| Total Costs & Expenses | $699425.00 | $643537.00 | $910327.00 | $801339.00 |
| Interest Income | $0.00 | $1864.00 | $2580.00 | $5665.00 |
| Interest Expense | $0.00 | $9803.00 | $12076.00 | $432.00 |
| Depreciation & Amortization | $17283.00 | -$9192.00 | $17027.00 | -$15870.00 |
| EBITDA | -$691560.00 | -$641510.00 | -$506391.00 | -$356185.00 |
| EBITDA Ratio | -$138.12 | -$55.18 | -$1.73 | -$0.86 |
| Operating Income | -$694418.00 | -$631911.00 | -$617914.00 | -$389175.00 |
| Operating Income Ratio | -$138.69 | -$54.35 | -$2.11 | -$0.94 |
| Other Income/Expenses (Net) | -$31263.00 | -$7738.00 | $101010.00 | $23394.00 |
| Income Before Tax | -$725681.00 | -$639649.00 | -$516904.00 | -$365781.00 |
| Income Before Tax Ratio | -$144.93 | -$55.02 | -$1.77 | -$0.89 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$725681.00 | -$639649.00 | -$516904.00 | -$365781.00 |
| Net Income Ratio | -$144.93 | -$55.02 | -$1.77 | -$0.89 |
| EPS | -$0.004 | -$0.004 | -$0.003 | -$0.002 |
| Diluted EPS | -$0.004 | -$0.004 | -$0.003 | -$0.002 |
| Weighted Avg Shares Outstanding | $172.78M | $158.84M | $161.53M | $149.36M |
| Weighted Avg Shares Outstanding (Diluted) | $172.78M | $158.83M | $161.53M | $149.31M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan